The Atlantic Report

Opioid Dependence Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

Opioid Dependence Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

September 26
04:53 2023
Opioid Dependence Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

DelveInsight’s, “Opioid Dependence Pipeline Insight 2023” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the Opioid Dependence pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Opioid Dependence pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Opioid Dependence Pipeline Report

  • DelveInsight’s Opioid Dependence pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Opioid Dependence treatment.
  • The leading companies working in the Opioid Dependence Market include Opiant Pharmaceuticals, Orexo, Aphios Pharma, DemeRx IB, Inc., Alar Pharmaceuticals, BioXcel Therapeutics, Lyndra Therapeutics, Trevena, Aptinyx, Indivior, Cerevel Therapeutics, BioCorRx, Delpor, AstraZeneca, Gilgamesh Pharmaceuticals, and others.
  • Promising Opioid Dependence Pipeline Therapies in the various stages of development include Probuphine (buprenorphine implant), Probuphine, sublingual buprenorphine tablets, VIVITROL® 380 mg, Medsignals, and others.
  • March 2023: Indivior Inc. announced a study of phase 4 clinical trials for Buprenorphine. This study is designed to determine if opioid dependent subjects who are already receiving Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex® to Suboxone®. Subjects who are selected to participate in this study will continue their prescribed dose of Subutex® (buprenorphine 2 to 16 mg daily) for the first two days of the study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone® (buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5).
  • June 2023: Hudson Medical announced a study of phase 1 clinical trials for Root.Health Dietary Supplement. This is a research study to evaluate the effectiveness of daily supplementation with Root.Health, a plant-based dietary supplement, on reducing levels of 11 abnormal urine biomarkers associated with chronic pain. Biomarkers are molecules found in blood, tissues, or other body fluids (such as urine) that indicate normal or abnormal processes.

 

Request a sample and discover the recent advances in Opioid Dependence Treatment Drugs @ Opioid Dependence Pipeline Report

 

In the Opioid Dependence pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Opioid Dependence clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Dependence collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Opioid Dependence Overview

Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The characteristic feature of dependence is a strong internal drive to use opioids, which manifests itself by an impaired ability to control use, increasing priority given to use over other activities, and persistence in use despite harm or negative consequences.

 

Find out more about Opioid Dependence Therapeutics Assessment @ Opioid Dependence Preclinical and Discovery Stage Products

 

Opioid Dependence Emerging Drugs Profile

  • OX 124: Orexo
  • APH-1501: Aphios
  • DMX-1002: DemeRx IB, Inc.
  • Noribogaine: DemeRx IB, Inc.

 

Opioid Dependence Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the Opioid Dependence therapies. The Opioid Dependence companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e. Preregistration Phase include, Orexo.

 

Learn more about the emerging Opioid Dependence Pipeline Therapies @ Opioid Dependence Clinical Trials Assessment

 

Scope of the Opioid Dependence Pipeline Report

  • Coverage- Global
  • Opioid Dependence Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Opioid Dependence Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Opioid Dependence Companies- Opiant Pharmaceuticals, Orexo, Aphios Pharma, DemeRx IB, Inc., Alar Pharmaceuticals, BioXcel Therapeutics, Lyndra Therapeutics, Trevena, Aptinyx, Indivior, Cerevel Therapeutics, BioCorRx, Delpor, AstraZeneca, Gilgamesh Pharmaceuticals, and others.
  • Opioid Dependence Pipeline Therapies- Probuphine (buprenorphine implant), Probuphine, sublingual buprenorphine tablets, VIVITROL® 380 mg, Medsignals, and others.

 

Dive deep into rich insights for new drugs for Opioid Dependence treatment, Visit @ Opioid Dependence Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Opioid Dependence Executive Summary
  3. Opioid Dependence: Overview
  4. Opioid Dependence Pipeline Therapeutics
  5. Opioid Dependence Therapeutic Assessment
  6. Opioid Dependence– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. OX 124: Orexo
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. APH-1501: Aphios
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Noribogaine: DemeRx IB, Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. GM-300X: Gilgamesh Pharmaceuticals
  18. Inactive Products
  19. Opioid Dependence Key Companies
  20. Opioid Dependence Key Products
  21. Opioid Dependence- Unmet Needs
  22. Opioid Dependence- Market Drivers and Barriers
  23. Opioid Dependence- Future Perspectives and Conclusion
  24. Opioid Dependence Analyst Views
  25. Opioid Dependence Key Companies
  26. Appendix

 

For further information on the Opioid Dependence pipeline therapeutics, reach out to Opioid Dependence Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

About Author

admin

admin